The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre

Histopathology

Volumn 62, Issue 4, 2013, Pages 609-616

  Conde, Esther ^a   Angulo, Bárbara ^a   Izquierdo, Elisa ^a   Muñoz, Luna ^a   Suárez Gauthier, Ana ^a   Plaza, Carlos ^a   Dominguez, Nuria ^a   Torres, Maribel ^a   Madrigal, Luis ^a   Rubio Viqueira, Belén ^a   Belda Iniesta, Cristobal ^a   Hidalgo, Manuel ^a   López Ríos, Fernando ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

ALK translocation; Lung cancer

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER CENTER; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SIGNET RING CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84874197111     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12037     Document Type: Article

References (46)

1. Riely GJ, Chaft JE, Ladanyi M, Kris MG. Incorporation of crizotinib into the NCCN guidelines. J. Natl. Compr. Canc. Netw. 2011; 9; 1328-1330.
2. Biology-driven medicine: tissue matters. Lancet Oncol. 2012; 13; 319.
3. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. WHO classification. Pathology and genetics-tumors of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
4. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011; 6; 244-285.
5. Conde E, Angulo B, Redondo P et al. The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS ONE 2010; 5; e12209.
6. García-García E, Gómez-Martín C, Angulo B et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology 2011; 59; 8-17.
7. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27; 4247-4253.
8. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 2009; 15; 5216-5223.
9. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010; 16; 1561-1571.
10. Yi ES, Boland JM, Maleszewski JJ et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 2011; 6; 459-465.
11. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harbouring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010; 16; 5581-5590.
12. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 2011; 6; 942-946.
13. Tanizaki J, Okamoto I, Okamoto K et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J. Thorac. Oncol. 2011; 6; 1624-1631.
14. Conde E, Angulo B, Suarez-Gauthier A et al. Assessment of MET amplification in non-small cell lung carcinomas by SISH: correlation with EGFR and KRAS mutations in early stages [abstract]. J. Thorac. Oncol. 2011; 6(Suppl. 2); P2.230.
15. Conde E, Angulo B, Tang M et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin. Cancer Res. 2006; 12; 710-717.
16. Angulo B, García-García E, Martínez R et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J. Mol. Diagn. 2010; 12; 292-299.
17. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad. Sci. USA 2011; 108; 7535-7540.
18. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010; 363; 1734-1739.
19. Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a Phase I dose escalation trial of an oral c-met and ALK inhibitor [abstract]. J. Clin. Oncol. 2009; 27(Suppl. 15s); 3509.
20. Fukui T, Yatabe Y, Kobayashi Y et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012; 77; 319-325.
21. Paik JH, Choi CM, Kim H et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012; 76; 403-409.
22. Wong DW, Leung EL, So KK et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115; 1723-1733.
23. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 2009; 22; 508-515.
24. Yoshida A, Tsuta K, Nakamura H et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am. J. Surg. Pathol. 2011; 35; 1226-1234.
25. Park HS, Lee JK, Kim DW et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012; 77; 288-292.
26. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363; 1693-703.
27. McLeer-Florin A, Moro-Sibilot D, Melis A et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J. Thorac. Oncol. 2012; 7; 348-354.
28. Salido M, Pijuan L, Martínez-Avilés L et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011; 6; 21-27.
29. Martelli MP, Sozzi G, Hernandez L et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 2009; 174; 661-670.
30. Perner S, Wagner PL, Demichelis F et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008; 10; 298-302.
31. Just PA, Cazes A, Audebourg A et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 2012; 76; 309-315.
32. Popat S, Gonzalez D, Min T et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer 2012; 75; 300-305.
33. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 2012; 106; 1100-1106.
34. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012; 13; 239-246.
35. Okayama H, Kohno T, Ishii Y et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012; 72; 100-111.
36. Jokoji R, Yamasaki T, Minami S et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J. Clin. Pathol. 2010; 63; 1066-1070.
37. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012; 18; 1472-1482.
38. Camidge DR, Doebele RC. Treating ALK-positive lung cancer - early successes and future challenges. Nat. Rev. Clin. Oncol. 2012; 9; 268-277.
39. De Castro-Carpeño J, Perona R, Belda-Iniesta C. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. Clin. Trans. Oncol. 2011; 13; 774-779.
40. Chaft JE, Rekhtman N, Ladanyi M, Riely GJ. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J. Thorac. Oncol. 2012; 7; 768-769.
41. Klempner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J. Thorac. Oncol. 2011; 6; 1439-1440.
42. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12; 1004-1012.
43. Rekhtman N, Paik PK, Arcila ME et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin. Cancer Res. 2012; 18; 1167-1176.
44. Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch. Pathol. Lab. Med. 2011; 135; 655-664.
45. Camidge DR, Theodoro M, Maxson DA et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non-small cell lung cancer. Cancer 2012; 118; 4486-3394.
46. Heuckmann JM, Balke-Want H, Malchers F et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin. Cancer Res. 2012; 18; 4682-4690.